Myriad Genetics, Inc. (MYGN)

NetscribeBiotech (77.10) Submitted: 3/12/07 5:18 AM : Start Price: $33.61 MYGN Score: -102.39

Myriad Genetics, Inc. (Myriad) is a biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products. The company focuses on therapeutic product development for diseases such as cancer, Alzheimer’s...

Report this Post Replies: 0 | Reply | Permalink

bethsheba (< 20) Submitted: 1/19/07 7:55 PM : Start Price: $35.90 MYGN Score: 91.79

Although the pipeline of drug targets and ever increasing acceptance and utilization of their predictive genetic testing products continues to keep this stock in a steady position with modest yet consistent growth I feel certain that this stock will...

Report this Post Replies: 1 | Reply | Permalink

TMFBreakerJava (99.26) Submitted: 6/06/06 5:56 AM : Start Price: $25.40 MYGN Score: 155.24

Predictive medicine is a growing business that finances the new drug development. Promising pipeline. Buy here, while the market has biotechs on sale.

Report this Post Replies: 0 | Reply | Permalink

pedrorojo (< 20) Submitted: 8/23/07 6:15 PM : Start Price: $42.97 MYGN Score: 64.24

Myriad is a rarity among smaller biotechs. It has a growing and viable revenue generator in it's personalized/predictive medicine business. Myriad uses the revenue from this very lucrative and highly profitable business to generate cash to fund drug ...

Report this Post Replies: 0 | Reply | Permalink

buryemdeep (83.07) Submitted: 2/02/08 10:42 PM : Start Price: $42.17 MYGN Score: 61.82

This area of medicine represents the "keys to the kingdom" when it come to curing major diseases like some cancers, leukemia and prostate cancer. This area of research has and will continue to change medicine!

Report this Post Replies: 0 | Reply | Permalink

Iznogoud888 (72.71) Submitted: 7/02/08 3:16 PM : Start Price: $52.83 MYGN Score: -22.32

Failed PIII Flurizan for AD and actually shot up on the news - Possibly because of new focus on successful molecular diagnostics business. However, the enthusiasm has gone a little too high as the stock is now trading at more that 75 times 2009E earn...

Report this Post Replies: 0 | Reply | Permalink

ResearchLover (95.05) Submitted: 5/29/08 4:16 PM : Start Price: $48.54 MYGN Score: -42.68

"Myriad Genetics . Target $37. RBC intiated MYGN with an Underperform and $37 tgt. Firm expects negative Phase III results from Flurizan for Alzheimer's disease based on: 1) the prior weak Phase II results and very small dataset, 2) subset analysis o...

Report this Post Replies: 0 | Reply | Permalink

Virtuehunter (63.70) Submitted: 10/16/06 9:02 PM : Start Price: $26.40 MYGN Score: 152.19

Myriad has made some great progress with a number of drugs. Their Alzheimer medication has the potential to revolutionize how we treat this disease that affects millions.

Report this Post Replies: 0 | Reply | Permalink

ahauben (58.97) Submitted: 8/31/07 2:58 PM : Start Price: $43.97 MYGN Score: 61.59

Myriad Genetics makes money on medical/genetic testing, which they will start to advertise on Oprah. They are supposed to have a solid treatment for Alzheimer's, in Phase III. Results have been good so far. Company is based in Salt Lake City.

Report this Post Replies: 0 | Reply | Permalink

zacprince (82.90) Submitted: 10/29/07 9:33 PM : Start Price: $55.14 MYGN Score: 34.32

fast money stem cells

Report this Post Replies: 0 | Reply | Permalink